- Home
- WTFCM vs GALT Comparison
WTFCM vs GALT Comparison
Compare WTFCM & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WTFCM
- GALT
- Stock Information
- Founded
- WTFCM N/A
- GALT 2000
- Country
- WTFCM United States
- GALT United States
- Employees
- WTFCM 5903
- GALT N/A
- Industry
- WTFCM Major Banks
- GALT Biotechnology: Pharmaceutical Preparations
- Sector
- WTFCM Finance
- GALT Health Care
- Exchange
- WTFCM Nasdaq
- GALT Nasdaq
- Market Cap
- WTFCM N/A
- GALT 83.5M
- IPO Year
- WTFCM N/A
- GALT N/A
- Fundamental
- Price
- WTFCM $25.00
- GALT $2.79
- Analyst Decision
- WTFCM
- GALT Buy
- Analyst Count
- WTFCM 0
- GALT 2
- Target Price
- WTFCM N/A
- GALT $6.00
- AVG Volume (30 Days)
- WTFCM N/A
- GALT 664.5K
- Earning Date
- WTFCM N/A
- GALT 08-12-2025
- Dividend Yield
- WTFCM N/A
- GALT N/A
- EPS Growth
- WTFCM N/A
- GALT N/A
- EPS
- WTFCM N/A
- GALT N/A
- Revenue
- WTFCM N/A
- GALT N/A
- Revenue This Year
- WTFCM N/A
- GALT N/A
- Revenue Next Year
- WTFCM N/A
- GALT N/A
- P/E Ratio
- WTFCM N/A
- GALT N/A
- Revenue Growth
- WTFCM N/A
- GALT N/A
- 52 Week Low
- WTFCM N/A
- GALT $0.73
- 52 Week High
- WTFCM N/A
- GALT $3.90
- Technical
- Relative Strength Index (RSI)
- WTFCM 34.03
- GALT 68.94
- Support Level
- WTFCM $24.94
- GALT $2.77
- Resistance Level
- WTFCM $24.99
- GALT $2.97
- Average True Range (ATR)
- WTFCM 0.01
- GALT 0.20
- MACD
- WTFCM -0.01
- GALT 0.04
- Stochastic Oscillator
- WTFCM 14.29
- GALT 91.11
About WTFCM Wintrust Financial Corporation Fixed-to-Floating Rate Non-Cumulative Perpetual Preferred Stock Series D
Wintrust Financial Corp is a financial holding company that provides community-oriented, personal, and commercial banking services to customers generally located in the Chicago metropolitan area, southern Wisconsin, northwest Indiana, and western Michigan. The company provides specialty finance services, including financing for the payment of property and casualty insurance premiums and life insurance premiums, and wealth management services to customers in its market area. The company's operations consist of three primary segments: community banking, specialty finance, and wealth management. The company generates the majority of its revenue from the community banking segment.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.